Clinical trials · Raleigh–Durham, NC
Down Syndrome clinical trials in Raleigh–Durham
We’re tracking 88 recruiting down syndrome studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT06366464RecruitingPhase 3
Study of a drug for sleepiness in Prader-Willi syndrome
This trial tests a medication called pitolisant to see if it helps reduce excessive daytime sleepiness in people with Prader-Willi syndrome. You or your loved one may be able to join if they have a confirmed diagnosis and a caregiver who can regularly help with study tasks.
Morrisville, North CarolinaAges 6 years+ - NCT07219485Enrolling by invitationPhase 3
Pitolisant for Prader-Willi syndrome in ongoing study
This study tests an oral medication, pitolisant, in people with Prader-Willi syndrome who have already been in a pitolisant study. It aims to see if continuing treatment is safe and effective.
Morrisville, North CarolinaAges 7 years+ - NCT05066217RecruitingPhase 3
Study tests clemizole for Lennox-Gastaut seizures
This Phase 3 trial studies whether clemizole helps reduce seizures in people with Lennox-Gastaut syndrome (LGS) and checks safety. If you have LGS and meet the seizure and heart-safety requirements, this could be an option to explore.
Morrisville, North CarolinaAges 2–55 - NCT04462770RecruitingPhase 3
Clemizole trial for children and adults with Dravet syndrome
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
Morrisville, North CarolinaAges 2 years+ - NCT01143480Recruiting
Testing how the body responds to endotoxin
This study checks how your immune system (your body’s defense system) reacts to a controlled substance that triggers inflammation. It may help researchers understand why some people have stronger or weaker inflammatory responses.
Research Triangle Park, North CarolinaAges 18–100 - NCT01276470Recruiting
Study of environmental triggers in anti-synthetase syndrome
This study looks for environmental risk factors that may be linked to anti-synthetase syndrome, a type of inflammatory muscle disease. It compares people with the condition to carefully matched people without it, using questionnaires, blood samples, and lung imaging when needed.
Research Triangle Park, North CarolinaAges 2–100 - NCT03836300Enrolling by invitation
Parent-infant coaching for families with young diagnoses
This study tests a parent-and-infant coaching program for babies and caregivers. It aims to see whether the program helps after an early diagnosis when English is used at home.
Research Triangle Park, North CarolinaAges Up to 99 years - NCT07706374RecruitingPhase 1
Does exemestane help women with PCOS ovulate?
This study tests if exemestane, a medication, can safely help women with PCOS start ovulating. It's for women who haven't tried ovulation medications before and are being treated at UNC Fertility.
Raleigh, North CarolinaAges 18–40 - NCT01137825Recruiting
Older patient cancer registry for a health check
This study is a registry that collects information from older adults who may be dealing with cancer. It includes a short health and function check to help doctors understand needs and guide care, even for people who turn out not to have cancer.
Raleigh, North CarolinaAges 65 years+ - NCT05905328RecruitingPhase 1/Phase 2
New drug to prevent and treat side effects of CAR T-cell therapy
This study tests an experimental drug, CTO1681, that may help prevent or treat cytokine release syndrome (CRS) — a common side effect of CAR T-cell therapy. It could make the recovery period safer and more comfortable.
Durham, North CarolinaAges 18 years+ - NCT04669548Recruiting
Accuryn monitoring study for people having heart surgery
This registry collects information from patients who are monitored with the Accuryn system during heart surgery and their ICU stay. It helps researchers learn from the system’s signals to better understand patient care around cardiac procedures.
Durham, North CarolinaAges 18 years+ - NCT06508164Recruiting
International registry for rare RYR2 variants
This study creates a registry for people with rare changes in the RYR2 gene that affect heart function. Researchers will collect information to better understand these conditions and improve care.
Durham, North CarolinaAges Any age - NCT07155226RecruitingPhase 1/Phase 2
Study of AZD3632 for advanced blood cancers with certain gene changes
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
Durham, North CarolinaAges 16 years+ - NCT07220187RecruitingPhase 3
Adding pirtobrutinib to usual treatment for newly diagnosed Richter transformation
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
Durham, North CarolinaAges 18 years+ - NCT06641414RecruitingPhase 3
Lisaftoclax with azacytidine for higher-risk myelodysplastic syndrome
This trial tests a new drug called lisaftoclax combined with a standard treatment, azacytidine, for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if the combination helps control the disease better than what's currently available.
Durham, North CarolinaAges 18 years+ - NCT06747949RecruitingPhase 3
Long term extension study of dazodalibep for Sjogren's syndrome
This study gives continued access to the study drug dazodalibep for people with Sjogren's syndrome who completed a prior phase 3 study. The goal is to see how safe and effective the medication is over a longer period.
Durham, North CarolinaAges 18 years+ - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Durham, North CarolinaAges 6–75 - NCT00482794Recruiting
Study genetic risk factors for antiphospholipid antibody syndrome
This study looks at genetic (inherited) risk factors in people who have antiphospholipid antibodies and related symptoms. Your results may help researchers better predict who is at risk and improve care for antiphospholipid antibody syndrome.
Durham, North CarolinaAges Any age - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Durham, North CarolinaAges 18–65 - NCT06395285RecruitingPhase 1
Testing DF-003 for ROSAH syndrome with eye inflammation
This trial tests an oral medication called DF-003 for people with ROSAH syndrome who have eye inflammation (uveitis). The goal is to see if the drug is safe and tolerable. It might help reduce eye inflammation and other symptoms.
Durham, North CarolinaAges 18–65 - NCT05905926Enrolling by invitationPhase 3
Tenapanor safety study for teens with constipation-predominant IBS
This trial checks the safety of tenapanor in children and teens (ages 6 to under 18) with IBS-C. It is only for people who finished a previous related study and agreed to continue follow-up.
Durham, North CarolinaAges 6–18 - NCT01186913Enrolling by invitation
Natural history study for severe combined immune deficiency (SCID)
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
Durham, North CarolinaAges Any age - NCT06872125RecruitingPhase 3
Testing zorevunersen for Dravet syndrome
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Durham, North CarolinaAges 2–17 - NCT06701656RecruitingPhase 2
Testing bevacizumab for breathing problems from ARDS
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
Durham, North CarolinaAges 18 years+
Hear when a new Down Syndrome trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Down Syndrome trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting down syndrome studies listed above.
- Duke University Medical Center · 10 studies
- Science 37 · 3 studies
- University of North Carolina at Chapel Hill · 3 studies
- National Institute of Environmental Health Sciences Clinical Research Unit · 2 studies
- UNC Lineberger Comprehensive Cancer Center · 2 studies
- Ascentage Investigative Site
- Duke Early Phase Clinical Research Unit - PPDS
- Duke Eye Center - Duke University Hospital
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting down syndrome studies in North Carolina.
Common questions
- Are there down syndrome clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 88 recruiting down syndrome studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.